Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.<br />
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center (MSK), discusses the rationale for the phase II study of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (ccRCC).
Combinations of anti-VEGF and PD-1/PD-L1 inhibitors have shown great efficacy in clinical studies involving patients with kidney cancer. The question then became whether these combinations would still be effective in patients who previously progressed on a PD-1 inhibitor. Because of the speculation surrounding the idea of treating patients with another immune checkpoint inhibitor after they progressed on one, researchers at MSK decided to launch a study.
The results of the interim analysis, which included 33 patients from the study, showed partial responses in 64% of patients at 24 weeks of follow-up. The study also demonstrated a median progression-free survival of 11.2 months.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
